Amylyx Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

AMLX$30.21+2.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Product revenue, net	$416	$102,693	$88,036	$272,337
Operating expenses:
Cost of sales	—	5,218	5,953	16,081
Cost of sales - inventory impairment and loss on firm purchase commitments	809	—	118,680	—
Acquired in-process research and development	36,203	—	36,203	—
Research and development	21,237	30,037	81,192	83,273
Selling, general and administrative	17,828	48,718	97,234	136,115
Restructuring expenses	—	—	22,851	—
Total operating expenses	76,077	83,973	362,113	235,469
(Loss) income from operations	(75,661)	18,720	(274,077)	36,868
Other income, net:
Interest income	3,098	4,179	11,493	11,784
Other expense, net	(141)	(488)	(1,371)	(831)
Total other income, net	2,957	3,691	10,122	10,953
(Loss) income before income taxes	(72,704)	22,411	(263,955)	47,821
Provision for income taxes	—	1,518	242	3,281
Net (loss) income	$(72,704)	$20,893	$(264,197)	$44,540
Net (loss) income per share
Basic	$(1.07)	$0.31	$(3.89)	$0.66
Diluted	$(1.07)	$0.30	$(3.89)	$0.63
Weighted-average shares used in computing net (loss) income per share
Basic	68,091,446	67,414,669	67,990,613	67,124,407
Diluted	68,091,446	69,748,547	67,990,613	70,143,659

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.